A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of bevacizumab plus irinotecan for the patients with
recurrent anaplastic astrocytoma or with recurrent glioblastoma multiforme